ISTH guidelines for antithrombotic treatment in COVID‐19

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, I...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of thrombosis and haemostasis Ročník 20; číslo 10; s. 2214 - 2225
Hlavní autoři:	Schulman, Sam, Sholzberg, Michelle, Spyropoulos, Alex C., Zarychanski, Ryan, Resnick, Helaine E., Bradbury, Charlotte A., Connors, Jean Marie, Falanga, Anna, Iba, Toshiaki, Kaatz, Scott, Levy, Jerrold H., Middeldorp, Saskia, Minichiello, Tracy, Ramacciotti, Eduardo, Samama, Charles Marc, Thachil, Jecko, Broxmeyer, Lisa, International Society on Thrombosis and Haemostasis
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Inc 01.10.2022 Elsevier Limited John Wiley and Sons Inc
Témata:	Aftercare anticoagulants Anticoagulants - adverse effects Coronaviruses COVID-19 critical illness Dosage Fibrinolytic Agents - adverse effects Heparin Heparin - adverse effects Heparin, Low-Molecular-Weight Hospitalization Humans Molecular weight Patient Discharge Patients platelet aggregation inhibitors Platelet Aggregation Inhibitors - adverse effects Recommendations and Guidelines Rivaroxaban Thromboembolism anticoagulants COVID‐19 critical illness platelet aggregation inhibitors COVID-19
ISSN:	1538-7836, 1538-7933, 1538-7836
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!